Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $66.1250.

VOR has been the topic of a number of analyst reports. Wedbush began coverage on Vor Biopharma in a research report on Tuesday, November 25th. They issued a “neutral” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Citigroup initiated coverage on Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright dropped their target price on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Finally, TD Cowen started coverage on Vor Biopharma in a research note on Wednesday, December 17th. They set a “buy” rating on the stock.

Vor Biopharma Stock Down 2.2%

Shares of Vor Biopharma stock opened at $12.78 on Friday. The stock has a market capitalization of $133.04 million, a P/E ratio of -0.03 and a beta of 2.02. The stock has a 50 day moving average price of $13.55 and a two-hundred day moving average price of $23.73. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. State Street Corp raised its position in Vor Biopharma by 905.7% in the 4th quarter. State Street Corp now owns 91,053 shares of the company’s stock valued at $1,191,000 after buying an additional 81,999 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 822.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 145,640 shares of the company’s stock worth $1,905,000 after purchasing an additional 129,854 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Vor Biopharma by 578.3% in the fourth quarter. Geode Capital Management LLC now owns 185,808 shares of the company’s stock worth $2,432,000 after acquiring an additional 158,416 shares during the period. Chung Wu Investment Group LLC purchased a new stake in shares of Vor Biopharma in the fourth quarter worth about $109,000. Finally, UBS Group AG grew its position in shares of Vor Biopharma by 284.8% during the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after purchasing an additional 216,209 shares in the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).